Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Sponsor: Rigel Pharmaceuticals
Summary
The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2019-10-30
Completion Date
2024-04
Last Updated
2022-03-17
Healthy Volunteers
No
Interventions
Fostamatinib disodium
Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
Locations (37)
University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory
Los Angeles, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, United States
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
John Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
American Oncology Network Vista Oncology Division
Olympia, Washington, United States
University of Washington
Seattle, Washington, United States
Princess Alexandra Hospital - Cancer Trials Unit
Brisbane, Queensland, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Hanusch-Krankenhaus
Vienna, Austria
Universitätsklinik f. Innere Medizin I - Klin. Abt. f. Hämatologie u. Hämostaseologie
Vienna, Austria
Vitebsk Regional Clinical Hospital
Vitebsk, Belarus
Vitebsk Regional Clinical Oncology Dispensary
Vitebsk, Belarus
AZ Nikolaas
Sint-Niklaas, Belgium
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD, Plovdiv, Clinic of Medical oncology
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Varna, Clinic of Clinical Haematology
Sofia, Bulgaria
Specialized Hospital for Active Treatment of Hematological Disease EAD,
Sofia, Bulgaria
Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika
Brno, Czechia
Fakultni nemocnice Ostrava Klinika hematoonkologie
Ostrava, Czechia
CHU de Bordeaux - GH Sud- Hôpital Haut Lévêque Service Médecine Interne et Maladies Infectieuses
Pessac, France
LTD Multiprofile Clinic Consilium Medulla
Tbilisi, Georgia
M. Zodelava Hematology Centre, Tbilisi
Tbilisi, Georgia
Universitätsklinikum Essen
Essen, Germany
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, UO Ematologia
Milan, Italy
Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico di Milano - UO Ematologia
Milan, Italy
SCDU Ematologia AOU "Maggiore della Carità"
Novara, Italy
Academisch Medisch Centrum
Amsterdam, Netherlands
Haukeland University Hospital
Bergen, Norway
National Research Center for Hematology
Moscow, Russia
State Budgetary Healthcare Institution Oncology Dispensary No. 2 of the Ministry of Health of the Krasnodar Territory
Sochi, Russia
Clinical Centre of Vojvodina, Clinic for Hematology
Novi Sad, Serbia
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
City Clinical Hospital № 4, Hematology Center
Dnipro, Ukraine
Kyiv City Clinical Hospital №9, hematology department №1
Kyiv, Ukraine
Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust
Liverpool, United Kingdom